[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413598":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":30,"responsibleParty":48,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pulmonary Langerhans cell histiocytosis (PLCH)",null,"All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses",[13],"Other: Standard of care",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Standard of care","Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)",[9],[20,26],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Abdellatif TAZI, MD PhD","CONTACT","142499198","33","abdellatif.tazi@aphp.fr",{"name":27,"role":22,"phone":28,"phoneExt":24,"email":29},"matthieu resche-rigon, MD PhD","142499742","matthieu.resche-rigon@u-paris.fr",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"French national reference centre for Histiocytoses","RECRUITING","Paris","75010","France","FR",{"type":39,"coordinates":40},"Point",[41,42],2.3488,48.85341,{"lat":42,"lon":41},[45,46],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},{"name":47,"role":22,"phone":28,"phoneExt":24,"email":29},"Matthieu RESCHE-RIGON, MD PhD",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100413598",false,"NCT04665674","Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study","Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":59,"type":60},500,"ESTIMATED","30 Years","OBSERVATIONAL","The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.",[65,66,67],"Histiocytosis","Histiocytosis, Langerhans-Cell","Histiocytosis Pulmonary","2020-12-15",{"date":70,"type":71},"2020-12-17","ACTUAL",{"date":73,"type":71},"2004-01-01",{"date":75,"type":60},"2035-12-31",{"name":5,"class":6},1]